In Regard to Bossi et al

Bossi et al undertook an independent evaluation of the NRG oropharynx squamous cell cancer nomograms (1, 2). To do so, they retrospectively extracted relevant data, some of which may be difficult to ascertain from the medical record (tobacco use, marital status, weight loss, performance status, education, and survival outcomes). Presumably, more than 184 patients with oropharynx cancer were treated at their high-volume center between 2004 and 2016. Perhaps it is not surprising that there appear to be distinct differences between the NRG clinical trial study populations and the Bossi et al clinical series.

https://ift.tt/2OoE2VC